M
Marek Krogulec
Researcher at Pfizer
Publications - 5
Citations - 630
Marek Krogulec is an academic researcher from Pfizer. The author has contributed to research in topics: Rheumatoid arthritis & Placebo. The author has an hindex of 2, co-authored 3 publications receiving 502 citations.
Papers
More filters
Journal ArticleDOI
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese,Joel M. Kremer,Omid Zamani,Charles Ludivico,Marek Krogulec,Li Xie,Scott D. Beattie,Alisa E. Koch,Tracy Cardillo,Terence Rooney,William L. Macias,Stephanie de Bono,Douglas E Schlichting,Josef S. Smolen +13 more
TL;DR: In patients with rheumatoid arthritis and an inadequate response to biologic DMARDs, baricitinib at a daily dose of 4 mg was associated with clinical improvement at 12 weeks and a small reduction in neutrophil levels and increases in serum creatinine and low-density cholesterol levels.
Journal ArticleDOI
Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
Paul Emery,Mohammed Hammoudeh,Oliver FitzGerald,Bernard Combe,Emilio Martín-Mola,Maya H Buch,Marek Krogulec,Theresa Williams,Stefanie Gaylord,Ronald Pedersen,Jack F. Bukowski,Bonnie Vlahos +11 more
TL;DR: In patients with early rheumatoid arthritis who had a remission while receiving full-dose etanercept-plus-methotrexate therapy, continuing combination therapy at a reduced dose resulted in better disease control than switching to methotrexate alone or placebo, but no significant difference was observed in radiographic progression.
Journal ArticleDOI
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study
Claire Daien,Marek Krogulec,Paul Gineste,J. M. Steens,L Desroys du Roure,Sophie Biguenet,Didier Scherrer,J De Santo,Hartmut J. Ehrlich,Patrick Durez +9 more
TL;DR: ABX464 50 mg was safe, well tolerated and showed a promising efficacy and warrant exploration of ABX464 at 50 mg per day or less for treating patients with RA, which may not be a relevant dose to use.
Journal ArticleDOI
Rheumatoid arthritis oral abstractsO01. Efficacy and Safety of Baricitinib Versus Placebo and Adalimumab in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Summary Results from the 52-Week Phase 3 RA-Beam Study
Peter C. Taylor,Marek Krogulec,Anna Dudek,Jean Dudler,Edit Drescher,Regina Cseuz,Rasa Kausiene,D. Andersone,Dalia Unikiene,Juan Sanchez Burson,R.B. Alonso,Zdeněk Dvořák,A Ghizdavescu,I. Irto,Esbjörn Larsson,N. Bello,Jane Barry,Frederick Durand,Thorsten Holzkämper,Susan Otawa,Stephanie de Bono,Edward C. Keystone,Andrea Rubbert-Roth,Bernard Combe,Inmaculada de la Torre +24 more
Journal ArticleDOI
Pos0688 phase 2a study in patients with moderate-to-severe rheumatoid arthritis and inadequate response to mtx and/or anti-tnfα therapeutics shows that oral abx464 50 mg once daily is safe, well tolerated and shows promising efficacy results
Claire Daien,Marek Krogulec,Philippe Gineste,J. M. Steens,L Desroys du Roure,Sophie Biguenet,Didier Scherrer,J. Santo,Heinz-Michael Ehrlich,Patrick Durez +9 more
TL;DR: Although the sample size of this proof-of-concept study was not powered to show efficacy, multiple early efficacy endpoints showed signs of promise with the ABX464 50 mg daily dose.